

Alexander G G Turpie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7205918/publications.pdf>

Version: 2024-02-01

43
papers

2,863
citations

279798

23
h-index

265206

42
g-index

43
all docs

43
docs citations

43
times ranked

4006
citing authors

#	ARTICLE	IF	CITATIONS
1	GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 214-227.	4.0	19
2	Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. <i>BMJ Open</i> , 2022, 12, e049933.	1.9	8
3	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	7.4	37
4	Comparative effectiveness of oral anticoagulants in everyday practice. <i>Heart</i> , 2021, 107, 962-970.	2.9	14
5	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021, 5, 1081-1091.	5.2	30
6	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309.	3.0	29
7	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. <i>Europace</i> , 2020, 22, 195-204.	1.7	22
8	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the <scp>XANTUS</scp> real-world prospective study. <i>Clinical Cardiology</i> , 2020, 43, 1405-1413.	1.8	2
9	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019, 21, 421-427.	1.7	10
10	Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 64-69.	3.0	19
11	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	1.5	8
12	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	3.4	28
13	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	3.4	76
14	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 70-79.	3.0	29
15	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
16	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018, 163, 132-137.	1.7	7
17	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 933-938.e1.	1.5	21
18	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018, 20, e87-e95.	1.7	13

#	ARTICLE	IF	CITATIONS
19	XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egyptian Heart Journal, 2018, 70, 307-313.	1.2	17
20	Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology, 2018, 72, 141-153.	2.8	48
21	Predictive value of venous thromboembolism (<sc>VTE</sc>)â€<sc>BLEED</sc> to predict major bleeding and other adverse events in a practiceâ€based cohort of patients with <sc>VTE</sc>: results of the <sc>XALIA</sc> study. British Journal of Haematology, 2018, 183, 457-465.	2.5	32
22	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2018, 46, 339-345.	2.1	10
23	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	2.5	80
24	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	2.9	205
25	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161
26	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
27	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUSâ€ACTS Substudy. Clinical Cardiology, 2016, 39, 565-569.	1.8	33
28	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
29	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal, 2016, 37, 1145-1153.	2.2	383
30	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
31	Trends in Prescribing Oral Anticoagulants in Canada, 2008â€2014. Clinical Therapeutics, 2015, 37, 2506-2514.e4.	2.5	124
32	Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vascular Health and Risk Management, 2014, 10, 157.	2.3	28
33	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vascular Health and Risk Management, 2014, 10, 425.	2.3	29
34	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. Expert Review of Cardiovascular Therapy, 2014, 12, 963-976.	1.5	0
35	Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study. Stroke, 2013, 44, 249-251.	2.0	26
36	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE, 2013, 8, e63479.	2.5	375

#	ARTICLE	IF	CITATIONS
37	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 309-323.	2.5	13
38	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012, 163, 13-19.e1.	2.7	195
39	Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. <i>Chest</i> , 2011, 140, 706-714.	0.8	401
40	Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S20-S24.	1.0	5
41	ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies. <i>BMJ: British Medical Journal</i> , 2002, 325, 948-950.	2.3	40
42	Setting a standard for venous thromboembolism prophylaxis. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, S18-S23.	1.0	2
43	Antithrombotic Therapy Following Heart Valve Replacement. <i>Thrombosis and Haemostasis</i> , 1997, 78, 382-385.	3.4	1